Nanoscope Announces Presentation at the 2020 Annual Meeting of American Academy of Ophthalmology

Nanoscope Therapeutics Announces Presentation at the 2020 Annual Meeting of American Academy of Ophthalmology

BEDFORD, Texas, Nov. 13, 2020 /PRNewswire/ — NANOSCOPE THERAPEUTICS Inc., a clinical- stage biotechnology company determined to change lives through the ocular gene therapy based on its proprietary ambient light activatable MCO Optogenetic Technology Platform, today announced that an oral presentation at the Late Breaking Developments session of Retina Subspecialty Day will be made during the American Academy Ophthalmology (AAO) 2020 Annual Meeting, taking place November 13-15, 2020.

The presentation will feature data from the vMCO-010 Phase 1/2a intravitreal trial for the treatment of Retinitis Pigmentosa (RP). Details are as follows:

Title: Phase 1/2a Study of Intravitreal Optogenetics Gene Therapy for Vision Restoration in Advanced Retinitis Pigmentosa
Presenter: Dr. Santosh Mahapatra, Chief Medical Ofcer, JPM Rotary Eye Hospital and Research Center
Date/time: 13th November 2020, 3.00 PM PST; also available on-demand Session title: Late Breaking Developments, Part IThe Nanoscope co-authors of the presentation are Sai Chavala (Chief Medical Ofcer), Samuel Barone (Advisor), Samarendra Mohanty (President and Chief Technology & Innovation Ofcer), Subrata Batabyal, Michael Carlson, Ananta Ayyagari, and Kissaou Tchedre.
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light- assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. We utilize an ambient light-sensitive Multi- Characteristic Opsin (MCO) molecule to re-sensitize the retina toward low light level. Our light- assisted gene therapy is highly targeted to geographic atrophies without perturbing the intact retina circuitry. Our team is highly experienced in Ophthalmology product development and clinical translation of innovative research. Our pipeline includes light based retinal regeneration therapy and light-based cortical prosthetics for vision restoration.
Sulagna Bhattacharya
Investor Relations and Corporate Communications
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186
  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.